Mark Dowling

Haematology registrar at @PeterMacCC, immunologist @WEHI_Research, ex-quantum physicist and new dad

[Pietro Di Ciaccio @prpdiciaccio]

Important work regarding high prevalence of BCMA expression in PBL.
There is no consensus in the treatment of RR PBL and anti BCMA therapies are intriguing.

Interestingly the two patients exposed to CD19 directed CART in this small series died. #lymsm

[Michael Dickinson @mike_dickinson1]

#CART and fixed #ibrutinib for #Mantle cell #lymphoma in @bloodjournal. More evidence that immunotherapy may help with high-risk molecular subtypes. Congrats to @adrianminson for driving this lightning-fast @petermacres IIT as part of his PHD! #lymsm https://t.co/nLFWCZxuzE

[Dr T. Comeau , MD @SCTNB]

Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations | Blood | American Society of Hematology https://t.co/fBaovSotXq

[NEJM @NEJM]

Late breaking at #ASCO23: In the phase 3 ZUMA-7 trial, patients with relapsed or refractory large B-cell lymphoma who received axi-cel (CD19-specific CAR T cells) had a 27.4% lower risk of death than patients who received standard therapy. Full trial results:

[Michael Dickinson @mike_dickinson1]

Zuma7 shows that, in spite of cross over in >50%, there is an OVERALL SURVIVAL BENEFIT for CAR-T (Axi-Cel) versus chemo+transplant for #DLBCL #lymphoma - the NEJM Paper is online! https://t.co/xbCIJJpoc0 #lymsm Great to have been a part of this practice-changing trial.

[Jordan Gauthier @drjgauthier]

Surprised this went through peer-review unnoticed...
What is the issue with the proposed analysis shown in the plot?
Very exciting data nonetheless!
https://t.co/T6igfiqfqX
@JCO_ASCO

[Leukaemia Foundation @LeukaemiaAus]

Each year we join forces with @LLSusa & @SnowdomeAU to identify & fund new translational research projects.
Congratulations Assoc. Professor Jane Oliaro @PeterMacRes and Professor Richard Lock @KidsCancerInst!
Learn more: https://t.co/Th2jxNzo12

[A/Prof Emily Blyth @EmilyBlyth5]

A welcome investment in medical technology - cell and gene therapy research and therapy.
https://t.co/w4r2yeaWAy
@WestSydHealth @WestmeadInst @NSWHealth

[Dylan O'Donnell 🦋 @erfmufn]

Physics Quiz! How many Hiroshimas/Megatons of explosive force does it take to get the Tennis off the front page of all major Australian news outlets? (Clue: it's more than 1000 Hiroshimas)

[Mark Dowling @markrdowling]

@StephenORahilly “Exponential” means increasing by a constant percentage per unit time, not just “big”

[Mark Dowling @markrdowling]

Dan Suan - Omicron warning https://t.co/DcsZ1OAoDP via @YouTube

[Graham Collins @graham74GC]

Bishop - Belinda
- Tisa-cel v SOC in 2L Agg NHL
- Refract or < 12mo 1L, bridging OK
- 1 EP: EFS - death or PD/SD at 12 week assessment
- 322 random, 33% SOC had ASCT
- Median EFS both arms 3mo
- 51% crossed to tisa-cel
tisa-cel < liso/Axi - or study design issue?
#ASH21 #lymsm

[Toby Eyre @tobyeyre82]

POLARIX PFS subgroup analysis in supplementary of @NEJM Well worth a look!
IPI 3-5 vs IPI 2 differences fairly striking.
#ASH21 #lymsm #DLBCL

[Jordan Gauthier @drjgauthier]

A fantastic opportunity to join our group @fredhutch @EvNewell1 as a Bioinformatics Analyst.
https://t.co/LMFo1tauaz
You will help us analyze high-dimensional proteomic/genomic data from CAR T cell patients (amongst other things!)
Please RT!
@xanhira @KrishnaRJuluri

[Mark Dowling @markrdowling]

@drjgauthier @rstatstweet Please tell me! And share your code 🤣

[Jordan Gauthier @drjgauthier]

Great review work carried out by Dr. @Razan_Mohty! 👍

[Doherty Institute @TheDohertyInst]

Statement on the Doherty Institute modelling:

The Doherty Institute understands how extremely challenging lockdown restrictions are for everyone.

[Mark Dowling @markrdowling]

@JoshCasan @Farehlab Nice work team!

[Joshua Casan @JoshCasan]

Thrilled to see our group’s paper out. https://t.co/4U1T4pYKvr Amongst the first demonstrating the potential for CRISPR-Cas13-based targeting of live SARS-CoV-2. Special congrats to the brilliant @Farehlab. Lucky to be part of this project as my first venture into basic science.

[Michael Dickinson @mike_dickinson1]

#ZUMA7 Is positive in favour of #CART #yescarta versus transplant in first high risk relapse of #DLBCL #lymphoma #lymsm. Incredibly exciting news and some actual numbers in the press release! Very exciting.
https://t.co/WQoLliplxU